Imagion Biosystems President and CEO Bob Proulx told Proactive Investors Australia, “in the medical imaging space today there’s no consumable that goes with it… with our technology, because it includes both the measuring instrument and an injectable component, there’s the classic printer-ink business model. We think that will be attractive for our commercial partner because now you’ll be able to not only sell and install and service the instrument, but you’ll also have the consumable that goes with each of the new tests that we bring to market.”
The company focuses on early detection and research for several types of cancer using nanoparticle diagnostic imaging technology.
More articles on biologics:
3 things to know about Lattice Biologics’ CEO
Cellect receives patent approval for Apograft technology: 3 notes
OsteoRemedies unveils 1st FDA-cleared dual-antibiotic spacer & bone cement: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
